Navigation Links
Breast cancer risk factors differ among races
Date:4/25/2010

A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.

Breast cancer occurs more frequently in certain ethnic and racial groups, but the reasons behind these differences are not fully understood. To investigate the issue, Lisa Hines, ScD, of the University of Colorado at Colorado Springs led a study that considered how established breast cancer risk factorsincluding reproductive history, family history of breast cancer, menstrual history, hormone use, alcohol consumption, physical activity, height, and body mass indexmight be involved in explaining some of the observed differences in the occurrence of breast cancer among racial and ethnic groups. They studied breast cancer among women from the Southwest United States who were enrolled in the population-based, case-control 4-Corners Breast Cancer Study, which was designed to investigate factors that contribute to the difference in breast cancer incidence rates observed between Hispanic and non-Hispanic white women.

Prior studies have shown that non-Hispanic white women have a higher incidence of breast cancer than Hispanic women. In this current study, the researchers found that 62 percent to 75 percent of breast cancer cases among non-Hispanic white women were attributed to known breast cancer risk factors, compared with only 7 to 36 percent of cases among Hispanic women. Hispanic women were more likely to have characteristics associated with lower breast cancer risk, such as earlier age at first childbirth, having more children, shorter height, less hormone use, and less alcohol consumption. Among premenopausal women, taller height and family history of breast cancer were associated with increased risk in non-Hispanic white women but were not among Hispanic women. Among postmenopausal women, certain breast cancer risk factors in non-Hispanic whites (such as recent hormone therapy use and younger age at menarche) had no or only weak associations with breast cancer in Hispanics.

These findings suggest that many of the risk factors studied to date explain fewer of the breast cancer cases that arise in Hispanic women compared with non-Hispanic white women. "These differences are likely to contribute to disparities in breast cancer incidence rates, and could potentially reflect differences in breast cancer development among these ethnic groups," said Dr. Hines. For example, ethnic differences in genetic and environmental or lifestyle factors may affect individuals' susceptibility to the development of breast cancer.

The authors noted that the study's findings also indicate that the use of models to estimate a woman's risk of breast cancer that were developed from studies among non-Hispanic white populations need to be evaluated among other ethnic and racial populations.


'/>"/>

Contact: Claire Greenwell
claire.greenwell@cancer.org
404-417-5883
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Targeted therapy prolongs life in patients with HER2-positive breast cancer
2. New Drugs, New Combinations Fight Breast Cancer
3. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
4. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
5. Prolactin blocks oncogene associated with poor prognosis in breast cancer
6. Definitive study confirms chemo benefit in postmenopausal breast cancer
7. Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients
8. Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer
9. Bone Drugs May Beat Back Breast Cancer
10. California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts
11. Alcohol consumption may increase breast cancer recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have ... from Pixel Film Studios. With ProSharpen Color users have total control over sharpening amount, ... their color range. With color spectrum tools users can visually see the color range ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of ... Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas ... easy access to Highway 121. , As the practice has grown, the need for ...
(Date:2/24/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces the ... body image mannequin art competition. Selected from 15 submissions from around the nation, the ... the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: